Compare BCML & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCML | RZLT |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.3M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | BCML | RZLT |
|---|---|---|
| Price | $32.40 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $32.00 | $12.33 |
| AVG Volume (30 Days) | 18.1K | ★ 9.8M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $94,896,000.00 | N/A |
| Revenue This Year | $0.51 | N/A |
| Revenue Next Year | $10.33 | N/A |
| P/E Ratio | $15.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.22 | $1.07 |
| 52 Week High | $32.98 | $11.46 |
| Indicator | BCML | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 76.69 | 22.97 |
| Support Level | $27.94 | $1.07 |
| Resistance Level | $31.62 | $11.17 |
| Average True Range (ATR) | 0.90 | 0.66 |
| MACD | 0.29 | -0.81 |
| Stochastic Oscillator | 98.95 | 7.23 |
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.